BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 37144531)

  • 21. Genetic Determinants of Circulating Lipoproteins in Nonalcoholic Fatty Liver Disease.
    Jiang ZG; Tapper EB; Kim M; Connelly MA; Krawczyk SA; Yee EU; Herman MA; Mukamal KJ; Lai M
    J Clin Gastroenterol; 2018; 52(5):444-451. PubMed ID: 28362682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2.
    Anstee QM; Day CP
    Semin Liver Dis; 2015 Aug; 35(3):270-90. PubMed ID: 26378644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PNPLA3 Genotype and Diabetes Identify Patients With Nonalcoholic Fatty Liver Disease at High Risk of Incident Cirrhosis.
    Chen VL; Oliveri A; Miller MJ; Wijarnpreecha K; Du X; Chen Y; Cushing KC; Lok AS; Speliotes EK
    Gastroenterology; 2023 May; 164(6):966-977.e17. PubMed ID: 36758837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.
    Krawczyk M; Rau M; Schattenberg JM; Bantel H; Pathil A; Demir M; Kluwe J; Boettler T; Lammert F; Geier A;
    J Lipid Res; 2017 Jan; 58(1):247-255. PubMed ID: 27836992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combining I148M and E167K variants to improve risk prediction for nonalcoholic fatty liver disease in Qingdao Han population, China.
    Chen LZ; Ding HY; Liu SS; Liu Q; Jiang XJ; Xin YN; Xuan SY
    Lipids Health Dis; 2019 Feb; 18(1):45. PubMed ID: 30738435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease.
    Wong CR; Nguyen MH; Lim JK
    World J Gastroenterol; 2016 Oct; 22(37):8294-8303. PubMed ID: 27729736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Promoting genetics in non-alcoholic fatty liver disease: Combined risk score through polymorphisms and clinical variables.
    Vespasiani-Gentilucci U; Gallo P; Dell'Unto C; Volpentesta M; Antonelli-Incalzi R; Picardi A
    World J Gastroenterol; 2018 Nov; 24(43):4835-4845. PubMed ID: 30487694
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The greater impact of PNPLA3 polymorphism on liver-related events in Japanese non-alcoholic fatty liver disease patients: A multicentre cohort study.
    Seko Y; Yamaguchi K; Shima T; Iwaki M; Takahashi H; Kawanaka M; Tanaka S; Mitsumoto Y; Yoneda M; Nakajima A; Fjellström O; Blau JE; Carlsson B; Okanoue T; Itoh Y
    Liver Int; 2023 Oct; 43(10):2210-2219. PubMed ID: 37470077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.
    Liu YL; Patman GL; Leathart JB; Piguet AC; Burt AD; Dufour JF; Day CP; Daly AK; Reeves HL; Anstee QM
    J Hepatol; 2014 Jul; 61(1):75-81. PubMed ID: 24607626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of PNPLA3, TM6SF2 and SAMM50 on the development and severity of non-alcoholic fatty liver disease in children.
    Lee KJ; Moon JS; Kim NY; Ko JS
    Pediatr Obes; 2022 Feb; 17(2):e12852. PubMed ID: 34490745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors.
    Dongiovanni P; Romeo S; Valenti L
    World J Gastroenterol; 2014 Sep; 20(36):12945-55. PubMed ID: 25278690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of PNPLA3 rs738409 Polymorphism on the Development of Liver-Related Events in Patients With Nonalcoholic Fatty Liver Disease.
    Rosso C; Caviglia GP; Birolo G; Armandi A; Pennisi G; Pelusi S; Younes R; Liguori A; Perez-Diaz-Del-Campo N; Nicolosi A; Govaere O; Castelnuovo G; Olivero A; Abate ML; Ribaldone DG; Fariselli P; Valenti L; Miele L; Petta S; Romero-Gomez M; Anstee QM; Bugianesi E
    Clin Gastroenterol Hepatol; 2023 Dec; 21(13):3314-3321.e3. PubMed ID: 37149016
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date.
    Cherubini A; Casirati E; Tomasi M; Valenti L
    Expert Opin Ther Targets; 2021 Dec; 25(12):1033-1043. PubMed ID: 34904923
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals.
    Donati B; Dongiovanni P; Romeo S; Meroni M; McCain M; Miele L; Petta S; Maier S; Rosso C; De Luca L; Vanni E; Grimaudo S; Romagnoli R; Colli F; Ferri F; Mancina RM; Iruzubieta P; Craxi A; Fracanzani AL; Grieco A; Corradini SG; Aghemo A; Colombo M; Soardo G; Bugianesi E; Reeves H; Anstee QM; Fargion S; Valenti L
    Sci Rep; 2017 Jul; 7(1):4492. PubMed ID: 28674415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic opportunities for the treatment of NASH with genetically validated targets.
    Lindén D; Romeo S
    J Hepatol; 2023 Oct; 79(4):1056-1064. PubMed ID: 37207913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps.
    Santos RD; Valenti L; Romeo S
    Atherosclerosis; 2019 Mar; 282():110-120. PubMed ID: 30731283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Linked PNPLA3 polymorphisms confer susceptibility to nonalcoholic steatohepatitis and decreased viral load in chronic hepatitis B.
    Pan Q; Zhang RN; Wang YQ; Zheng RD; Mi YQ; Liu WB; Shen F; Chen GY; Lu JF; Zhu CY; Zhang SY; Chen YM; Sun WL; Fan JG
    World J Gastroenterol; 2015 Jul; 21(28):8605-14. PubMed ID: 26229402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores.
    De Vincentis A; Tavaglione F; Jamialahmadi O; Picardi A; Antonelli Incalzi R; Valenti L; Romeo S; Vespasiani-Gentilucci U
    Clin Gastroenterol Hepatol; 2022 Mar; 20(3):658-673. PubMed ID: 34091049
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of HSD17B13 and PNPLA3 With Liver Enzymes and Fibrosis in Hispanic/Latino Individuals of Diverse Genetic Ancestries.
    Rutledge SM; Soper ER; Ma N; Pejaver V; Friedman SL; Branch AD; Kenny EE; Belbin GM; Abul-Husn NS
    Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2578-2587.e11. PubMed ID: 36610497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetics and epigenetics of NAFLD and NASH: Clinical impact.
    Eslam M; Valenti L; Romeo S
    J Hepatol; 2018 Feb; 68(2):268-279. PubMed ID: 29122391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.